Agilent Technologies: Excellent Business, Impolite Price
The business and its moat
Agilent Technologies is not, at heart, a manufacturer so much as a piece of infrastructure — a toll booth standing at the entrance of pharmaceutical and biotech laboratories around the world. Its vast installed base of instruments generates recurring revenue from consumables and services, the kind of revenue that arrives whether or not anyone is feeling cheerful about the macro environment.
The moat here is physical measurement. In an era enamored with software replacing everything, the act of measuring molecules remains stubbornly analog. Instruments age, reagents run out, service contracts renew. That is a durable annuity, and AI will not be collecting the toll instead.
Earning power and capital allocation
The five-year average return on equity is 21.7%, with a standard deviation of just 1.6 percentage points. That consistency is the more interesting figure — capital efficiency that barely wobbles is rarer than capital efficiency that occasionally dazzles.
Annual owner earnings sit comfortably in line with the $200 million of free cash flow generated in the most recent quarter, which at least suggests the annual figure is not a work of fiction.
On capital allocation: a 20% dividend payout ratio reflects welcome discipline. The same cannot quite be said for the shrinking of share buybacks in a high-PE environment, which the note views as a lapse in prudence. Capital discipline with a hole in it is still discipline with a hole in it.
Valuation and margin of safety
The stock trades at $159.00. Wall Street’s consensus is a BUY, from 19 analysts with an average price target of $160.89 — a target, one notices, barely above the current price. Enthusiasm of a distinctly modest kind.
The estimated owner earnings yield is 2.6%. The 10-year US Treasury yields 4.74%. A risk-free instrument out-earns this business’s cash generation by nearly two points, which is not a valuation so much as a confession.
Applying a 30% margin of safety to the upper end of intrinsic value ($17.8 billion) implies a purchase price of about $12.5 billion, or roughly $44 per share. The current price sits at approximately a 250% premium to that intrinsic value ceiling. Quality, yes; price, entirely disconnected from it. Wall Street’s fondness for the near-term numbers notwithstanding, the safety margin has not been ignored — it has been abolished.
Word for today
An excellent business at an excessive price is the most dangerous combination a value investor can face. Until “a good company” arrives at “a good price,” the Oracle remains, contentedly, a spectator.
Verdict: pass.
Correction (2026-09-03): market cap and owner-earnings yield restated at the price on the verdict date ($159.00 on 2026-08-23; the 2026-08-17 screening snapshot adjusted for price): market cap ≈ $45.0 billion (the article did not state one), owner-earnings yield ≈ 2.63% (the article said 2.6%) vs the 10-year Treasury at 4.74% — verdict unchanged.
This analysis is AI-generated, educational, and not investment advice. Figures may contain errors or be delayed. Disclaimer